+357 96 030922
info@marketpublishers.com

Global LAG-3 Targeting Therapy Market, Drug Dosage, Patent, Sales & Clinical Trials Insight 2030

https://marketpublishers.com/r/GF139B5E6020EN.html
Date: April 2025
Pages: 190
Price: US$ 2,400.00 (Single User License)
ID: GF139B5E6020EN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Global LAG-3 Targeting Therapy Market, Drug Dosage, Patent, Sales & Clinical Trials Insight 2030 Report Findings & Highlights:

Global LAG-3 Targeting Therapies Market Opportunity By 2030: > USD 4 Billion

Global & Regional Market Insight

Approved Drug Global & Regional Sales Analysis

Approved LAG-3 Drug Dosing, Pricing & Sales Insight

Global LAG3 Inhibitors clinical Trials Insight By Company, Country, Indication and Phase

Insight On More Than 35 LAG-3 Targeted Therapies In Clinical Trials

Expected Completion Time For Key Drugs In Clinical Trials

The potential of LAG-3 targeting therapy to treat a number of ailments, particularly cancer, autoimmune diseases, and inflammatory diseases, has attracted a lot of attention to the global market. An immune checkpoint receptor called lymphocyte-activation gene 3 (LAG-3) is essential for controlling immune responses. As a result, a number of treatments have been developed to modify LAG-3 activity, either by

+357 96 030922
info@marketpublishers.com

activation, depletion, or inhibition, each with unique therapeutic uses. The most popular strategy among them is LAG-3 inhibition, but LAG-3 activation and depletion, both of which were developed by Immutep, are also becoming more popular.

In this market, LAG-3 inhibition is still the most popular therapeutic strategy because it aims to improve the immune system's capacity to recognize and eliminate cancer cells. The approach primarily involves the use of monoclonal antibodies, which are intended to inhibit the LAG-3 receptor, effectively maximizing T-cells to attack tumor cells. Bispecific antibodies, such as ZGGS-15, which targets both TIGIT and LAG-3, represent an upcoming and innovative class of therapies. Suzhou Zelgen Biopharmaceuticals' ZGGS-15 is specifically designed to treat solid tumors. Bispecific antibodies have the potential to increase the effectiveness of immune therapies by simultaneously targeting two immune checkpoint pathways, particularly for complex conditions like solid tumors that are typically more difficult to treat.

In addition to cancer, researchers are also looking into how LAG-3 targeting might be used to treat autoimmune and inflammatory disorders. Although research in this area is still in its early stages, there is also mounting evidence that suggests LAG-3 modulation may have therapeutic benefits in microbial diseases. The main focus, however, is still on cancer treatment, especially in the context of immunotherapy, where LAG-3 inhibition is thought to be a means of overcoming immune suppression brought on by tumors.

The drug Opdualag, which combines the anti-PD-1 monoclonal antibody nivolumab with the anti-LAG-3 monoclonal antibody relatlimab, is a significant success story in this field. Approved in 2022, Opdualag's revenue surpassed US$ 250 million that year, and in 2024, it exceeded US$ 900 million. This remarkable expansion indicates a promising future for similar treatments and reflects the growing acceptance of LAG-3 targeting therapies in the oncology market.

More than 35 LAG-3 targeting candidates are presently undergoing clinical development, demonstrating the expansive interest and continuous innovation in this area. Regeneron Pharmaceuticals is a major player in this market thanks to Fianlimab, one of its lead candidates. Fianlimab, which is presently undergoing Phase 3 trials, is being evaluated for a number of cancer indications and could have considerable effects on the treatment environment. Immutep's IMP-761, a first-in-class LAG-3 agonist, is another exciting candidate. IMP-761 is being tested for safety and effectiveness in humans in early phase trials, after which, the treatment will be expanded to autoimmune disorders.

+357 96 030922
info@marketpublishers.com

Thus, the increasing number of clinical trials and the expanding therapeutic indications for LAG-3 targeting therapies indicate this market is positioned for substantial growth in the coming years. The amalgamation of monoclonal and bispecific antibodies, along with the ongoing pursuit of LAG-3 agonism and depletion, presents a wide array of potential treatments that could revolutionize the management of cancer, autoimmune diseases, and beyond. LAG-3 targeted therapies are anticipated to become increasingly essential in immuno-oncology and other immune-related disorders as research advances, propelling additional market growth.

+357 96 030922
info@marketpublishers.com

Contents

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Global LAG-3 Targeting Therapy Market, Drug Dosage, Patent, Sales & Clinical Trials Insight 2030

Product link: https://marketpublishers.com/r/GF139B5E6020EN.html

Price: US$ 2,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/GF139B5E6020EN.html